CARTHERICS GRANTED EUROPEAN PATENT FOR MULTIPLE DEVELOPMENT CANDIDATES
23 May 2024
Immunotherapy
Melbourne, Australia, 23 May 2024 – Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has been granted its second European Patent from the family represented by the international patent filing WO2017088012.
The European Patent No. 3708587 B1, titled 'Genetically Modified Cells and Uses Thereof,' secures a proprietary position for multiple development candidates in the Company’s pipeline.
Specifically, this patent covers stem cells bearing the Cartherics’ chimeric antigen receptor (CAR) targeting the tumour-associated glycoprotein-72 (TAG-72). It also provides protection for allogeneic (off-the-shelf) immune cell products derived from the stem cells carrying the TAG-72 CAR.
TAG-72 is highly expressed on a range of adenocarcinomas, including ovarian and gastric cancers. Issuance of the patent is an important milestone in the development of new treatments for these cancers and adds to Cartherics’ substantial intellectual property portfolio.
Cartherics’ initial target indication is relapsed or refractory ovarian cancer, where greater than 90 percent of tumours are TAG-72 positive. Targeting these tumours with novel cellular immunotherapies will help address the unmet need for new treatment options for these patients.
Cartherics’ CEO, Prof. Alan Trounson AO, commented: “Cartherics has invested heavily to secure patent protection for different aspects of its technology platform. The issuance of this European patent adds to the web of patents underpinning development and commercialisation of the Company’s products, in particular its lead product, CTH-401.”
******
About Cartherics
Cartherics is a privately held biotechnology company based in Melbourne, Australia that is rearming the body’s immune system to fight cancer. It is developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products. The Company’s allogeneic (“off-the-shelf”) cell platform is based upon induced pluripotent stem cells (iPSCs) generated from donated cord blood that can be differentiated into NK cells, T cells and other cells of the immune system. The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells. The Company’s lead product, CTH-401, is a CAR-NK cell product. It carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.
Media contact
Christine Filippis
Teraze Communications
Phone: +61 419 119 866
Email: christine@teraze.com.au
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.